soul trial oral semaglutide cardiovascular outcomes 2024 nejm results A⬇️rate of eGFR decline in people with #T2D and a history of disease treated with in the อ่านเพิ่มฟรีที่: https://diabetesjournals.org/care/article-pdf/doi/10.2337/dc25-1080/848963/dc251080.pdf Presented at #ERA24: FLOW trial:

Patients with active inflammation, recent hospitalizations, or frequent flares are at higher risk for adverse outcomes

Microdosing Semaglutide involves taking lower doses of the medication, with the primary goal of supporting long-term health and longevity rather than treating diabetes or driving significant weight loss

Based on the positive results of these clinical trials, the American Diabetes Association and European Association for the Study of Diabetes Consensus Report recommend the use of GLP-1RAs for treating patients with T2DM with atherosclerotic CVD and/or multiple coronary risk factors [8]

Fat loss doesnt operate like that

Mammalian target of rapamycin (mTOR) signaling pathway and traumatic brain injury: A novel insight into targeted therapy

for subcutaneous semaglutide and tirzepatide in a large cohort study or subcutaneous semaglutide and liraglutide in a randomized trial (25, 26)